UMIN ID: UMIN000000704
Registered date:02/05/2007
Cancer therapy with vaccination using HLA-A24-restricted peptide from human vascular endothelial growth factor receptor 2: a phase I study in patients with unresectable colorectal cancer
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | unresectable colorectal cancer |
Date of first enrollment | 2006/07/01 |
Target sample size | 6 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | Vaccination |
Outcome(s)
Primary Outcome | Safety |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | 20years-old |
---|---|
Age maximum | 75years-old |
Gender | Male and Female |
Include criteria | |
Exclude criteria | pregnancy uncontroled infection uncontroled cerebral metastasis etc, |
Related Information
Primary Sponsor | Institute of Medical Science, University of Tokyo |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Government |
Secondary ID(s) |
Contact
public contact | |
Name | |
Address | Japan |
Telephone | |
kanamoto@ims.u-tokyo.ac.jp | |
Affiliation | Institute of Medical Science, University of Tokyo surgery and Bioengineering |
scientific contact | |
Name | Kanamoto Akira |
Address | 4-6-1,Shiroganedai,Minato-ku,Tokyo,Japan Japan |
Telephone | |
Affiliation | Institute of Medical Science, University of Tokyo surgery and Bioengineering |